The company is always looking to have 12 months of financial resources on hand. They are currently at that level. So, they are either quite hopeful of getting a money deal in the very near future or we are looking at dilution. I would imagine that much of the selling at $1.40 and slightly above is from those trying to set a price for dilution. Evidently, this is speculation on my part. Should we get a money deal, that ceiling will be lifted and we are off to the races with a tight share structure in place. The alternative is dilution IMHO. I don't view dilution as all evil....especially if it is a bought deal near current levels and provides funding to move key programs such as Herceptin forward in an expeditious manner. Bfw